N-Boc-2,2-dimethyl-4-ethenyloxazolidine | 1404311-95-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: N-Boc-2,2-dimethyl-4-ethenyloxazolidine
• 英文别名: Tert-butyl 2,2-dimethyl-4-vinyloxazolidine-3-carboxylate；tert-butyl 4-ethenyl-2,2-dimethyl-1,3-oxazolidine-3-carboxylate
• CAS: 1404311-95-0
• 化学式: C₁₂H₂₁NO₃
• 分子量: 227.304
• InChiKey: SEDZCRLQHSPEFD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-Boc-2,2-dimethyl-4-ethenyloxazolidine 在 Dowex 50W strong H⁺ resin 、 水 作用下， 以 甲醇 为溶剂， 生成 (S)-叔丁基-1-羟基丁-3-烯-2-基碳酸酯 、 2-甲基-2-丙基[(2R)-1-羟基-3-丁烯-2-基]氨基甲酸酯
  参考文献：
  名称：

  Synthesis of chiral vinylglycines

  摘要：

  (R)- or (S)-benzyl 4-formyl-2,2-dimethyl-3-oxazolidinecarboxylate (7a) and (R)- or (S)-1,1-dimethylethyl 4-formyl-2,2-dimethyl-3-oxazolidinecarboxylate (7b), readily available from serine, react with Wittig reagents to give alkenes 8. Selective deprotection followed by oxidation of the resulting unsaturated amino alcohols 9 provides vinylglycines 5 of defined configuration (> 95% ee) and double-bond geometry. D-Vinylglycines are obtained from L-serine, and conversely, D-serine gives beta,gamma-unsaturated amino acids with the L configuration. The double-bond geometry is controlled by the nature of the phosphorous ylide employed. The scope and limitations of this new methodology for the preparation of chiral vinylglycines is examined.

  DOI：

  10.1021/jo00013a023
• 作为产物：
  描述：

  3-反-溴碳-2,2'-二甲基氧酸酯 、 methyl triphenylphosphonium bromide 以66%的产率得到
  参考文献：
  名称：

  MORIWAKE, TOSHIO;HAMANO, SHIN-ICHI;SAITO, SEIKI;TORII, SIGERU, CHEM. LETT.,(1987) N 10, 2085-2088

  摘要：

  DOI：

文献信息

• [EN] MACROCYCLES AS PIM INHIBITORS<br/>[FR] MACROCYCLES EN TANT QU'INHIBITEURS DE PIM
  申请人：AMGEN INC

  公开号：WO2014022752A1

  公开（公告）日：2014-02-06

  The invention relates to compounds of formula (1), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

  该发明涉及式（1）的化合物及其盐。在某些实施例中，该发明涉及Pim-1和/或Pim-2以及/或Pim-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中，该发明涉及包含本文所披露的化合物的药物组合物，以及它们在预防和治疗与Pim激酶相关的疾病和病症，尤其是癌症中的用途。
• [EN] COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE<br/>[FR] COMPOSÉ POUR LE TRAITEMENT ET LA PROPHYLAXIE DE LA MALADIE DU VIRUS RESPIRATOIRE SYNCYTIAL
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013020993A1

  公开（公告）日：2013-02-14

  A compound of formula (I), as well as pharmaceutically acceptable salt thereof, wherein R1 to R10, A, Q, X and Y are as defined in description and in claims, can be used as a medicament for the treatment of respiratory syncytial virus.

  式（I）的化合物，以及其药学上可接受的盐，其中R1至R10，A，Q，X和Y如描述和索赔中定义的，可用作治疗呼吸道合胞病毒的药物。
• 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES
  申请人：Galley Guido

  公开号：US20100029589A1

  公开（公告）日：2010-02-04

  The invention relates to compounds of formula I wherein R 1 , R 2 , X, Y, and n are defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The invention also provides pharmaceutical compositions and methods of manufacture of such compounds. The compounds are useful for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases are depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  该发明涉及公式I的化合物，其中R1、R2、X、Y和n在规范中定义，并且其药学上可接受的酸盐。该发明还提供了制备这种化合物的药物组合物和方法。这些化合物可用于治疗与痕量胺相关受体的生物功能相关的疾病，这些疾病包括抑郁症、焦虑症、躁郁症、注意缺陷多动障碍、与压力有关的疾病、精神疾病、精神分裂症、神经系统疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、物质滥用和代谢紊乱、进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和吸收异常、体温稳态异常、睡眠和昼夜节律异常、心血管疾病。
• [EN] FACTOR XIIA INHIBITORS<br/>[FR] INHIBITEURS DU FACTEUR XIIA
  申请人：UNIV LEEDS INNOVATIONS LTD

  公开号：WO2019186164A1

  公开（公告）日：2019-10-03

  This invention relates to compoundsof formula (I)and methods of treatment using the compounds. The invention also relates to processes and methods for producing the compounds of the invention. The compounds of the invention are modulators of Factor XII (e.g. Factor XIIa). In particular, the compounds are inhibitors of Factor XIIa and may be useful as anticoagulants.

  本发明涉及公式(I)的化合物以及使用这些化合物进行治疗的方法。该发明还涉及用于生产该发明化合物的过程和方法。该发明化合物是凝血因子XII（例如凝血因子XIIa）的调节剂。具体来说，这些化合物是凝血因子XIIa的抑制剂，可能作为抗凝血剂有用。
• Aminoalkylphosphonates and related compounds as edg receptor agonists
  申请人：Budhu J Richard

  公开号：US20060089334A1

  公开（公告）日：2006-04-27

  The present invention encompasses compounds or Formula (I): as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.

  本发明涵盖化合物或式（I）及其药学上可接受的盐和水合物。这些化合物可用于治疗免疫介导的疾病和病状，例如骨髓、器官和组织移植排斥。还包括药物组合物和使用方法。